XOMA Royalty Corp.
HealthcareNASDAQ:XOMA · NASDAQ Global Market
-$0.01 today
Vol 0.13M · Avg 0.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$36.2M of revenue converted into $31.5M of net income for the selected period. Gross margin is 94.6% and net margin is 166.3%, showing how much revenue survives after costs and taxes. EPS is $1.57, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52.1M +83.1% | $28.5M +498.7% | $4.8M -21.1% | $6.0M -84.2% | $38.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.0M +1337.4% | $206.0K +44.1% | $143.0K -47.8% | $274.0K +60.2% | $171.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $49.2M +73.9% | $28.3M +512.8% | $4.6M -19.8% | $5.8M -84.9% | $38.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.3% -5.0pp | 99.3% +2.3pp | 97.0% +1.5pp | 95.5% -4.1pp | 99.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.7M -40.5% | $2.9M +1910.5% | $143.0K -6.5% | $153.0K -10.5% | $171.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.1M +4.7% | $34.5M +26.8% | $27.2M +17.2% | $23.2M +13.3% | $20.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $37.8M -44.6% | $68.3M +46.9% | $46.5M +100.6% | $23.2M +13.2% | $20.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.0M +1275.9% | $216.0K -76.0% | $900.0K +228.5% | $274.0K +64.1% | $167.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $47.8M +981.8% | -$5.4M +76.0% | -$22.6M -33.9% | -$16.8M -202.0% | $16.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 91.7% +110.7pp | -19.0% +455.2pp | -474.2% -194.7pp | -279.5% -322.8pp | 43.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $11.4M +128.5% | -$40.0M +4.5% | -$41.8M -140.3% | -$17.4M -199.3% | $17.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.8% +162.2pp | -140.3% +739.2pp | -879.5% -590.6pp | -288.9% -334.9pp | 45.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 -100.0% | $694.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.0M -5.8% | $13.8M +2332.3% | $569.0K | $0 -100.0% | $461.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $20.4M -0.3% | $20.5M +1915.4% | $1.0M +244.7% | $295.0K +118.0% | -$1.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $31.8M +263.3% | -$19.5M +52.3% | -$40.8M -138.5% | -$17.1M -207.7% | $15.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 61.0% +129.4pp | -68.4% +789.8pp | -858.2% -574.1pp | -284.0% -325.7pp | 41.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $103.0K +101.8% | -$5.7M | $0 +100.0% | -$15.0K -116.5% | $91.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $31.7M +329.4% | -$13.8M +66.2% | -$40.8M -138.7% | -$17.1M -208.3% | $15.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 60.8% +109.3pp | -48.5% +809.6pp | -858.2% -574.4pp | -283.8% -325.2pp | 41.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +192.7% | -$2 +59.2% | -$4 -104.0% | -$2 -387.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +188.5% | -$2 +59.2% | -$4 -104.0% | -$2 -404.6% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $18.0M +53.7% | $11.7M +2.0% | $11.5M +0.5% | $11.4M +1.1% | $11.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $18.0M +53.7% | $11.7M +2.0% | $11.5M +0.5% | $11.4M -6.4% | $12.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XOMA generate?
XOMA Royalty Corp. (XOMA) reported $52.15M of revenue in fiscal 2025.
Is XOMA profitable?
XOMA Royalty Corp. (XOMA) reported $31.71M of net income, with a net margin of 60.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.